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Abstract
Background: The amount of epicardial adipose tissue (EAT) has been demonstrated to correlate with the severity
of coronary artery disease (CAD) and the CAD activity.
The aim of this study is to assess the impact of EAT on long term clinical outcomes in patients with ST elevation
myocardial infarction (STEMI) after percutaneous coronary intervention (PCI).
Methods: We analyzed the data and clinical outcomes of 761 patients (614 males, 57 ± 12 year-old) with STEMI
who underwent successful primary PCI from 2003 to 2009. All patients were divided into two groups: thick EAT
group, EAT≥ 3.5 mm and thin EAT group, EAT < 3.5 mm. The primary end points were all-cause death, recurrent MI,
target vessel revascularization (TVR) and major cardiac adverse events (MACEs), composite of all-cause death,
recurrent MI and TVR, within 5 years.
Results: Median and mean EAT of 761 patients were 3.3 mm and 3.6 ± 1.7 mm, respectively. Mean follow up period
was 46 ± 18 months. MACE-free survival rate in the thick EAT group was significantly lower than in the thin EAT
group (log-rank P = 0.001). The event-free survival rate of all-cause death of the thick EAT group was significantly
lower than that of the thin EAT group (log-rank P = 0.005). The TVR-free survival rate in the thick EAT group was
significantly lower than in the thin EAT group (log-rank P = 0.007). The event-free survival rate of recurrent MI were
not significantly different between the groups (log-rank P = 0.206). In the Cox’s proportional hazard model, the
adjusted hazard ratio of thick EAT thickness for TVR was 1.868 (95% confidence interval 1.181–2.953, P = 0.008).
Conclusion: This study demonstrates that the EAT thickness is related with long term clinical outcome in patients
with STEMI. The EAT thickness might provide additional information for future clinical outcome, especially TVR.
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Background
The amount of epicardial adipose tissue (EAT) has been
demonstrated to correlate with the severity of coronary
artery disease (CAD) and the CAD activity [1, 2]. Our
previous study demonstrated that EAT thickness was
closely related with short term clinical outcomes in
patients with significant CAD after successful percutan-
eous coronary intervention (PCI) [3]. There has been
few study demonstrating the effect of EAT on long term
clinical outcomes in patients with ST elevation myocar-
dial infarction (STEMI).
Systemic inflammation has a pivotal role in adverse
outcomes in patients with STEMI [4–6]. As the meta-
bolically active EAT could amplify inflammation [7, 8],
the additional local inflammation of EAT might influ-
ence the adverse outcomes. Thus, EAT quantification
might provide additional information for future events
in patients with STEMI.* Correspondence: shinjh@ajou.ac.kr
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The aim of this study is to assess the impact of EAT
on long term clinical outcomes in patients with STEMI
after successful PCI.
Methods
The study population consisted of patients admitted to
Ajou University Medical Center for STEMI from 2003
to 2009. We consecutively enrolled 30-day survivors
after STEMI, who underwent successful PCI. Successful
PCI was defined as thrombolysis in myocardial infarc-
tion trial (TIMI) grade 3 flow and < 30% residual stenosis
in the infarct related artery after primary percutaneous
coronary intervention (PCI). The medical records of all
patients were retrospectively reviewed. This study was
approved by the Ajou University Hospital Institutional
Review Board (approval number: AJIRB-MED-MDB-12-
277). We excluded patients from the study if they had
history of prior revascularization. We also excluded
patients if the LV dysfunction was caused by any of the
following: predisposing cardiomyopathy, severe valvular
heart disease including symptomatic aortic stenosis,
more than moderate aortic and mitral regurgitation. As
active inflammation, such as infection or systemic auto-
immune disease, often related to increased EAT [9, 10],
we also excluded patients from the study if they had
active inflammation.
Two-dimensional transthoracic echocardiography was
performed within 48 h of primary PCI. Recordings of
three cycles of the two-dimensional parasternal long-
axis view were obtained. Images were enlarged for better
visualization and accurate measurement of EAT thick-
ness. EAT thickness was measured on the free wall of
the right ventricle (RV) in a still image at end diastole
on the parasternal long-axis view. EAT thickness was
measured at the point on the free wall of the RV at
which the ultrasound beam was oriented perpendicularly
to the aortic annulus [11–14]. The anterior echo-lucent
space between the linear echo-dense parietal pericar-
dium and the RV epicardium was considered to be EAT.
We measured the thickest point of EAT in each cycle.
The average value of the EAT thickness was calculated.
All patients were divided into two groups: thick EAT
group, EAT thickness ≥ 3.5 mm and thin EAT group,
EAT thickness < 3.5 mm. As the median value of EAT
thickness in patients with unstable presentation or
significance of coronary artery disease was 3.5 mm in
our previous studies [1, 2, 15], we chose 3.5 mm as a
reference. The primary end points were all-cause death,
recurrent MI, target vessel revascularization (TVR) and
major cardiac adverse events (MACEs), composite of all-
cause death, recurrent MI and TVR, within 5 years.
Recurrent MI was defined according to the universal
definition of MI [16]. The TVR was defined as clinically
indicated percutaneous or surgical revascularization of
the index vessel during follow-up. At 5 years after index
STEMI, follow-up data were obtained by reviewing med-
ical records and/or telephone interview with patients.
SPSS 13.0 statistical software package (SPSS, Chicago,
Illinois, USA) was used for all calculations. Data are
shown as the mean ± standard deviation for continuous
variables and as numbers and percentages for categorical
variables. Comparisons were conducted by unpaired
Student’s t test for continuous variables and Pearson chi-
square test for categorical variables. Event free survival
analysis for patients in these groups was performed using
the Kaplan-Meier method, and the differences between
groups were assessed by the log-rank test. To assess the
adjusted relative hazard ratio (HR) of EAT thickness to
the study end points, Cox’s proportional hazard model
was used with potential variables associated with clinical
outcomes. Adjusted covariates for the Cox’s proportional
hazard model were age, gender, diabetes mellitus, hyper-
tension, smoking, dyslipidemia, Killip classification, left
ventricular ejection fraction and thick EAT thickness
(≥3.5 mm). The results of Cox’s regression analysis were
expressed as adjusted HRs and their 95% confidence inter-
vals (CI) for clinical outcomes. Multivariate logistic regres-
sion analysis was performed to assess the effect of EAT
thickness on clinical outcomes. Null hypotheses of no
difference were rejected if P values were < 0.05.
Results
Total 761 patients (614 males, 57 ± 12 year-old) were
enrolled. Median and mean EAT of 761 patients were
3.3 mm and 3.6 ± 1.7 mm, respectively. Three hundred
fifty patients (46%) were included in the thick EAT group
and the others were included in the thin EAT group (411
patients, 54%). Patients in the thick EAT group were older
(61 ± 12 vs. 54 ± 12 year-old, P < 0.001), had less males (72
vs. 88%, P < 0.001), less smokers (59 vs. 69%, P = 0.003)
and more history of hypertension (45 vs. 34%, P = 0.002)
than the patients in the thin EAT group. The laboratory
findings did not show any significant difference at index
STEMI. There was no significant difference in medical
treatments between the groups (Table 1). Baseline data of
angiography and echocardiography are listed in Table 2.
The baseline characteristics of angiography were similar
in both groups. There was no significant difference in the
results of echocardiographic findings in both groups.
Patients were followed up for 46 ± 18 months after
index STEMI. The MACEs occurred in 142 patients
(19%). Of 761 patients, 62 patients (8%) died, 29 patients
(4%) experienced recurrent MI and 81 patients (11%)
needed TVR. In the thick EAT group, more MACEs
occurred (23 vs. 15%, P = 0.004), more patients died (11
vs. 6%, P = 0.006) and more patients needed TVR (13 vs.
9%, P = 0.042). Rate of recurrent MI was not significantly
different between the groups (7 vs. 4%, P = 0.189).
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Kaplan-Meier analysis (Fig. 1) revealed that MACE-
free survival rate in the thick EAT group was signifi-
cantly lower than in the thin EAT group (log-rank P =
0.001). The survival of the thick EAT group was signifi-
cantly worse than the thin EAT group (log-rank P =
0.005). In addition, The TVR-free survival rate in the
thick EAT group was significantly lower than in the thin
EAT group (log-rank P = 0.007). The event-free survival
curves for freedom of recurrent MI were not signifi-
cantly different between the groups (log-rank P = 0.206).
The multivariate survival analysis using Cox’s regression
model are reported in Table 3. In the Cox’s proportional
hazard model, age was strongly related to MACEs (HR
1.036, 95% CI 1.020–1.054, P < 0.001). Age (HR 1.098, 95%
CI 1.070–1.128, P < 0.001), Killip classification (HR 1.329,
95% CI 1.031–1.714, P = 0.028) and LVEF (HR 0.971, 95%
CI 0.948–0.995, P = 0.02) were related to all cause of death.
The adjusted HR of thick EAT thickness for TVR was
1.868 (95% CI 1.181–2.953, P = 0.008). In a multivariate
regression model, the EAT thickness was independently
associated with increased risk for all-cause mortality and
TVR (HR 6.394, 95% CI 1.779–11.009, P = 0.007 and HR
5.846, 95% CI 1.576–10.117, P = 0.007, Table 4).
Discussion
The present study demonstrated the close relationship
between EAT thickness by echocardiography and in-
creased rate of adverse clinical outcomes in patients with
STEMI who underwent successful PCI.
Accompanied by the concept of early intervention in
patients with STEMI and improvements in medications,
cardiovascular mortality after STEMI has declined [17].
Although the number of patients with severe LV dys-
function, presence of residual myocardial ischemia or
extent electrical instability, known as predictors for car-
diovascular mortality [18], have significantly decreased,
risk stratification after AMI still remains important [19].
Technical improvements in coronary intervention also
resulted in absence of residual myocardial ischemia or
extent electrical instability. In the present study, none had
severe LV dysfunction, residual myocardial ischemia or
extent electrical instability owing to early intervention.
Table 1 Baseline clinical characteristics
Variables EAT≥ 3.5 mm EAT < 3.5 mm P value
(n = 350) (n = 411)
Age (year-old) 61 ± 12 54 ± 12 <0.001
Men, n (%) 253 (72) 361 (88) <0.001
BMI (kg/m2) 24 ± 3 25 ± 3 0.331
Medical History
Hypertension, n (%) 157 (45) 140 (34) 0.002
Diabetes Mellitus, n (%) 81 (23) 77 (19) 0.138
Dyslipidemia, n (%) 25 (7) 32 (8) 0.737
Previous CVA, n (%) 11 (3) 12 (3) 0.858
Smoking, n (%) 206 (59) 285 (69) 0.003
LDL cholesterol (mg/dl ) 106 ± 32 102 ± 34 0.079
hs-CRP (mg/L) 1.3 ± 3 1.1 ± 3 0.46
Killip class
Killip class 3, n (%) 26 (7) 27 (7) 0.643
Killip class 4, n (%) 12 (3) 16 (4) 0.734
Medication at discharge
Beta-blocker, n (%) 234 (67) 292 (71) 0.214
ACE inhibitor, n (%) 230 (66) 257 (63) 0.362
ARB, n (%) 110 (31) 135 (33) 0.677
CCB, n (%) 61 (17) 64 (16) 0.491
statin, n (%) 245 (70) 277 (67) 0.441
EAT epicardial adipose tissue, BMI body mass index, CVA cerebrovascular
accident, LDL low-density lipoprotein, hs-CRP high sensitivity C-reactive pro-
tein, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker,
CCB calcium channel blocker
Table 2 Baseline angiographic and echocardiographic
characteristics
Variables EAT≥ 3.5 mm EAT < 3.5 mm P value
(n = 350) (n = 411)
Culprit lesion
LAD, n (%) 193 (55) 224 (55) 0.86
LCX, n (%) 32 (9) 30 (7) 0.355
RCA, n (%) 124 (35) 153 (37) 0.608
LM, n (%) 0 (0) 4 (1) 0.045
Coronary Artery Disease
1 vessel disease, n (%) 145 (41) 191 (46) 0.163
2 vessel disease, n (%) 118 (34) 128 (31) 0.451
3 vessel disease, n (%) 87 (25) 92 (22) 0.423
PCI
BMS, n (%) 68 (19) 77 (19) 0.566
DES, n (%) 276 (79) 331 (81) 0.808
Echocardiographic findings
LVEDD (mm) 50 ± 5 50 ± 5 0.159
LVESD (mm) 34 ± 6 34 ± 6 0.3
LVEDV (mL) 87 ± 19 88 ± 23 0.789
LVESV (mL) 45 ± 14 45 ± 14 0.885
LVMI (g/m2) 115 ± 28 114 ± 32 0.554
LVEF (%) 52 ± 10 51 ± 10 0.861
WMSI 1.51 ± 0.34 1.52 ± 0.34 0.751
Ischemic MR, n (%) 8 (2) 7 (2) 0.565
EAT epicardial adipose tissue, LAD left anterior descending artery, LCX left
circumflex artery, RCA right coronary artery, LM left main artery, PCI primary
coronary intervention, BMS bare metal stent, DES drug eluting stent, LVEDD
left ventricular end diastolic dimension, LVESD left ventricular end systolic
dimension, LVEDV left ventricular end diastolic volume, LVESV left ventricular
end systolic volume, LVMI left ventricular mass index, LVEF left ventricular
ejection fraction, WMSI wall motion score index, MR mitral regurgitation
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We could not find effect of angiographic and echocardio-
graphic parameters on clinical outcomes, except LVEF on
all cause of death, resulting from relatively good global
and regional LV function and complete revascularization
of the study population. Although these well-known pre-
dictors are still valid, additional predictors after STEMI
should be evaluated for improving clinical outcomes.
The infarcted cardiomyocytes results in release of their
intracellular contents and initiates an intense inflamma-
tory reaction [20]. Necrotic cells and damaged extracel-
lular matrix release endogenous damage-associated
molecular pattern molecules (DAMPs). In the injured
myocardium, DAMPs may potently stimulate inflamma-
tory cascades by stimulating the toll-like receptor (TLR)
family [21–23]. Generation of reactive oxygen species
(ROS) in the infarcted cardiomyocytes also directly
induces pro-inflammatory cascades, resulting in gener-
ation of active interleukin (IL)-1, the prototypical pro-
inflammatory cytokines that drives expression of
inflammation mediators [20, 24]. Most of studies found
that systemic inflammation independently predicts
MACE [4–6].
In STEMI, inflammatory cells are functionally acti-
vated [25, 26]. After PCI, functionally active neutrophil
infiltration is aggravated locally in the balloon-injured
arteries [27]. Endothelial activation and expression of
adhesion molecules such as selectins and intercellular
adhesion molecule (ICAM)-1 aggravate adhesion and
recruitment of neutrophils [28]. Locally infiltrated
neutrophil mediates destabilization of atherosclerotic
plaques [29]. Owing to the anatomic proximity to the
coronary arteries, metabolically active EAT has an
Fig. 1 Kaplan-Meier survival curves for free of adverse outcomes in the thick epicardial adipose tissue (EAT) group and the thin EAT group.
MACEs, major adverse cardiovascular events; EAT, epicardial adipose tissue; MI, myocardial infarction
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additional atherogenic inflammatory effect on culprit le-
sions [2, 7]. The paracrine and vasocrine secretions of
inflammatory adipokines by EAT, such as IL-1, IL-6,
ICAM, tumor necrosis factor-α and nerve growth factor,
contributes to the amplification of vascular inflammation
[7]. Although plasma inflammatory biomarkers might not
adequately reflect local inflammation, the presence of
inflammatory adipokines by EAT might reflect the re-
sponse to plaque rupture and perivascular inflammation
adjacent to atherosclerotic lesions [30]. Through add-
itional local vascular inflammation, the presence of meta-
bolically active adipose stores that surround epicardial
coronary arteries could contribute toward the adverse
clinical outcomes in patients with STEMI.
The present study has several limitations. First, echo-
cardiography is not the optimal methods for exact quan-
tification of total EAT. Although EAT thickness by
echocardiography does not exactly represent the amount
of total EAT, EAT thickness by echocardiography corre-
lates well with total EAT measured by computed tomog-
raphy or magnetic resonance imaging [11, 31]. The
majority of clinical studies have reported excellent intra-
and inter-observer agreement for the measurement of
EAT thickness by echocardiography on the parasternal
long-axis view [1, 11–13, 31]. Although there is still
debate of echocardiographic measurement techniques
and some studies have measured EAT thickness at end-
systole [14], EAT thickness by echocardiography at end-
diastole was well correlated with total amount of EAT in
our previous studies [1, 11]. Measurement of EAT thick-
ness by echocardiography might be reliable and relatively
accurate. Second, a normal-cut off value of EAT thick-
ness by echocardiography has not yet been established.
As ethnic differences could influence the distribution of
EAT [32], the cut-off value of EAT thickness by echocar-
diography for predicting adverse clinical outcomes might
be different according to the ethnicity. Also, there is
possibility of gender difference, as estrogen status could
affect the accumulation of visceral adipose tissue [33]. In
the present study, we could not demonstrate the gender
difference in the relationship between EAT and clinical
outcomes, owing to relatively small sample size of
females with MACEs. Further studies might be needed
for clinical application.
Table 3 Cox’s regression analysis for the adverse outcomes
Variables Adjusted Hazard ratio (95% CI) P value
MACEs
Age 1.036 (1.020–1.054) <0.001
Gender 0.997 (0.626–1.587) 0.99
Hypertension 0.945 (0.668–1.336) 0.747
Diabetes 1.318 (0.895–1.942) 0.162
Dyslipidemia 0.361 (0.114–1.147) 0.084
Smoking 1.289 (0.862–1.928) 0.217
Killip classification 1.135 (0.937–1.375) 0.197
LVEF 0.993 (0.977–1.009) 0.379
EAT thickness≥ 3.5 mm 1.382 (0.973–1.961) 0.07
All-cause mortality
Age 1.098 (1.070–1.128) <0.001
Gender 0.935 (0.484–1.805) 0.842
Hypertension 1.022 (0.611–1.71) 0.934
Diabetes 1.501 (0.832–2.705) 0.177
Dyslipidemia 0 (0–3.801) 0.97
Smoking 1.768 (0.952–3.282) 0.71
Killip classification 1.329 (1.031–1.714) 0.028
LVEF 0.971 (0.948–0.995) 0.02
EAT thickness≥ 3.5 mm 1.110 (0.637–1.934) 0.712
Recurrent MI
Age 1.001 (0.965–1.038) 0.966
Gender 0.64 (0.207–1.761) 0.356
Hypertension 0.624 (0.27–1.445) 0.271
Diabetes 0.952 (0.359–2.527) 0.921
Dyslipidemia 0.657 (0.087–4.985) 0.685
Smoking 1.767 (0.661–4.72) 0.256
Killip classification 0.838 (0.472–1.487) 0.546
LVEF 1.017 (0.982–1.053) 0.351
EAT thickness≥ 3.5 mm 1.661 (0.771–3.577) 0.195
TVR
Age 0.999 (0.978–1.021) 0.932
Gender 1.389 (0.674–2.86) 0.932
Hypertension 0.794 (0.493–1.28) 0.794
Diabetes 1.624 (0.987–2.672) 0.056
Dyslipidemia 0.989 (0.35–2.796) 0.984
Smoking 1.219 (0.7–2.123) 0.484
Killip classification 1.050 (0.792–1.391) 0.734
LVEF 1.007 (0.986–1.027) 0.532
EAT thickness≥ 3.5 mm 1.868 (1.181–2.953) 0.008
MACEs major adverse cardiovascular events, LVEF left ventricular ejection
fraction, EAT epicardial adipose tissue, MI myocardial infarction, TVR target
vessel revascularization, CI confidence interval
Table 4 Multivariate logistic regression analysis of the epicardial
adipose tissue thickness for adverse outcomes
Variables Hazard ratio (95% CI) P value
MACEs 0.03 (-0.039–0.1) 0.389
All-cause mortality 6.394 (1.779–11.009) 0.007
Recurrent MI 1.031 (-5.659–7.721) 0.762
TVR 5.846 (1.576–10.117) 0.007
MACEs major adverse cardiovascular events, MI myocardial infarction, TVR
target vessel revascularization, CI confidence interval
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Conclusions
This study demonstrates that the EAT thickness is related
with long term clinical outcome in patients with STEMI.
The EAT thickness might provide additional information
for future clinical outcome, especially TVR.
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